Scipher Medicine Increases Patient Access for Prismra® by Expanding Intended Use in Autoimmune Patients
29 juil. 2021 09h22 HE
|
Scipher Medicine Corporation
Expanded intended use for the blood test validated in Network-004 study.Now, most rheumatoid arthritis patients can be tested at any point in their clinical journey.Test enables providers to identify...
Scipher Medicine Announces PrismRA® Met Primary and Secondary Endpoints in Prospective Observational Study Predicting Inadequate Response to World’s Largest-Selling Drug Class
24 juin 2021 08h00 HE
|
Scipher Medicine Corporation
Blood Test Predicts TNFi Response in Patients Both Naïve to and Experienced with TherapyProviders Can Access Patient-Specific Data for Optimized Therapy Selection WALTHAM, Mass., June 24, 2021 ...
InvestorBrandNetwork (IBN) Announces Latest Episode of The Bell2Bell Podcast featuring Hugh Rogers, CEO of XPhyto Therapeutics Corp.
17 juin 2021 09h00 HE
|
XPhyto Therapeutics Corp.
NEW YORK, June 17, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- InvestorBrandNetwork (“IBN”), a multifaceted communications organization engaged in connecting public companies to the investment...
Phigenix, Inc. Announces Issuance of U.S. Patent Covering Precision Medicine Diagnostic and Novel Therapeutic for Treating Drug-Resistant Breast Cancer
15 juin 2021 12h17 HE
|
Phigenix, Inc.
ATLANTA, June 15, 2021 (GLOBE NEWSWIRE) -- Phigenix, Inc. Pharmaceutical and Biomedical Research Company, a molecular oncologist-led, biopharmaceutical company focused on identifying, developing,...
Scipher Medicine Presents New Data at the European League Against Rheumatism (EULAR) 2021 Further Validating PrismRA® Test
15 juin 2021 08h00 HE
|
Scipher Medicine Corporation
Molecular signature test predicts likelihood of non-response to adalimumab or etanercept, two of the world’s most expensive medications, in an independent validation cohort PrismRA demonstrates a more...
Federal report calls for DOJ, HHS adoption of federal accessibility standards for medical and diagnostic equipment
20 mai 2021 12h08 HE
|
National Council on Disability
WASHINGTON, May 20, 2021 (GLOBE NEWSWIRE) -- Today, the National Council on Disability (NCD)--an independent federal agency--released a report focused on much needed federal regulations that would...
Aeterna Zentaris Commences Pivotal Phase 3 DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency
13 mai 2021 08h05 HE
|
Aeterna Zentaris Inc
– Safety and efficacy study for macimorelin initiated as agreed with U.S. FDA and the European Medicines Agency ("EMA") in the Company's Pediatric Investigation Plan ("PIP") – Patient enrollment on...
Fluidigm Announces Virtual Mass Cytometry Webinar Investor Event on May 24, 2021, at 1:00 p.m. Eastern Time
10 mai 2021 13h30 HE
|
Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., May 10, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive...
Fluidigm Announces First Quarter 2021 Financial Results with Total Revenue of $32.8 Million, Up 19 Percent Over Prior Year Period
06 mai 2021 16h05 HE
|
Fluidigm Corporation
Forecasting underlying base business growth of 16–17% supported by new product innovation SOUTH SAN FRANCISCO, Calif., May 06, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an...
Fluidigm Announces Conference Call and Webcast of First Quarter 2021 Financial Results
08 avr. 2021 08h30 HE
|
Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., April 08, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive...